MRCF invests in San Diego ophthalmic biotech company, clinical trials to take place in Australia

February 28, 2018

Okogen, a San Diego developer of ophthalmic anti-infective drugs, announces AU$13 million in Series A Funding from Brandon Capital’s Medical Research Commercialisation Fund (MRCF) to advance its viral conjunctivitis treatment.

The MRCF has a trainee/secondee program, whereby Member Institutes or allied public sector initiatives can nominate staff members to work within the Investment Manager for periods ranging from 1 – 6 months.